HEALTH PROFESSIONAL · SOURCE READING

Antiangiogenic and Other Targeted Therapy

Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage IV and Recurrent Renal Cell Cancer

A growing understanding of the biology of cancer in general, and renal cell cancer in particular, has led to the development and U.S. Food and Drug Administration (FDA) approval of six new agents that target specific growth pathways. Two of the approved targeted therapies block the mammalian target of rapamycin (mTOR), a serine/threonine protein kinase that regulates cell growth, division, and survival.

Continue within this section

Anti-vascular endothelial growth factor (VEGF) and multitargeted tyrosine kinase inhibitors (TKIs) →Mammalian target of rapamycin (mTOR) inhibitors →Hypoxia-inducible factor (HIF)-2alpha inhibitors →

Preserved source evidence · Not medical advice